Mark Moasser, M.D.

University of California, San Francisco
email: mmoasser@medicine.ucsf.edu

Grants

Understanding HER3 and mTor Signaling in Breast Cancer 2012 (Cycle 18)
IDEA (Innovative, Developmental, and Exploratory Awards) 18IB-0030 $100,000
Towards Highly Effective Inactivation of HER2-HER3 Signaling 2010 (Cycle 16)
Translational Research Awards 16OB-0150 $744,957
HER3 Infidelity and Resistance to Tyrosine Kinase Inhibitors 2005 (Cycle 11)
IDEA (Innovative, Developmental, and Exploratory Awards) 11IB-0069 $150,000


Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin doi:10.1007/s10549-016-3698-y
  Periodical: Breast Cancer Research and Treatment
  Author(s): MR Campbell, H Zhang, S Ziaee, A Ruiz-Saenz, N Gulizia, J Oeffinger, DN Amin, et al.
  Yr: 2016 Vol: 155 Nbr: 3 Pgs: 431-40
  Associated Grant: Towards Highly Effective Inactivation of HER2-HER3 Signaling
 
Effective treatment of HER2-amplified breast cancer by targeting HER3 and 1 integrin doi:10.1007/s10549-016-3698-y
  Periodical: Breast Cancer Research and Treatment
  Author(s): M R. Campbell, H Zhang, S Ziaee, A. Ruiz-Saenz, N Gulizia, J Oeffinger, D N Amin, et al.
  Yr: 2016 Vol: 155 Nbr: 3 Pgs: 431-40
  Associated Grant: Understanding HER3 and mTor Signaling in Breast Cancer
 
Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer.
  Periodical: Journal of Clinical Oncology
  Author(s): Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, et al.
  Yr: 2014 Vol: 32 Nbr: Pgs: 1472-1479
  Associated Grant: Towards Highly Effective Inactivation of HER2-HER3 Signaling
 
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
  Periodical: Nature
  Author(s): Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.
  Yr: 2007 Vol: 445 Nbr: Pgs: 437-41
  Associated Grant: HER3 Infidelity and Resistance to Tyrosine Kinase Inhibitors